Schildge, S., Bohrer, C., Beck, K
The pharmaceutical companies adoption of a financialized business model prioritizes profits and shareholder returns through an aggressive strategy for securing additional patents for minor changes to extend their drugs market exclusivity well beyond the expiration of its original patents, according to a report released Thursday by the Initiative for Medicines, Access and Knowledge on the heavy price of those glucagon-like
While the biotech industry has long leaned on TOC, its broader application across the pharmaceutical and medical device sectors could revolutionize how we justify "clean." Read the full article to see how a single TOC result can be evaluated against multiple cleaning limits to provide a "worst-case" security blanket for your facility
F.G.: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Medimmune, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis